AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

H.C. Wainwright downgraded AnaptysBio (ANAB) to Neutral from Buy with a price target of $19, down from $52, after the company announced topline ...

AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...

San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...

ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be ...

AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a ...

The clinical-stage biotechnology company said its investigational drug ANB032 didn't meet either primary or secondary endpoints in its 201-patient Arise-AD trial as a therapy for atopic dermatitis, ...

BTIG downgraded AnaptysBio (ANAB) to Neutral from Buy without a price target The company’s topline data from the Phase 2b trial of ANB032 in atopic dermatitis are expected later in December and ...

On Monday, BTIG adjusted its stance on AnaptysBio (NASDAQ ... braces for topline data from its Phase 2b trial of ANB032 in atopic dermatitis, expected later in December. According to InvestingPro ...

On Monday, BTIG adjusted its stance on AnaptysBio (NASDAQ: NASDAQ ... braces for topline data from its Phase 2b trial of ANB032 in atopic dermatitis, expected later in December. According to ...

Especially in atopic dermatitis. The success of AnaptysBio’s product candidates will depend on their ability to differentiate their drug candidates versus established companies like AbbVie and ...